Sectors
NBTX
Nanobiotix S.A.
39.33
4 x 39.12
4 x 39.45
bid
ask
+
3.15
8.69%
09:36 AM
timesize
| Ytd | 70.09% | |
| 1y | 432.86% |
39.09
day range
39.42
6.97
52 week range
57.14
| Open | 39.27 | Prev Close | 36.18 | Low | 39.09 | High | 39.42 | Mkt Cap | 1.99B |
| Vol | 17.89K | Avg Vol | 97.06K | EPS | -0.59 | P/E | -66.45 | Forward P/E | -112.79 |
| Beta | 0.78 | Short Ratio | 0.87 | Inst. Own | 11.75% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-31 | 50-d Avg | 37.68 | 200-d Avg | 30.17 | 1yr Est | 45.06 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-09-29 | 2026-06 | -0.13 | N/A | N/A | N/A |
| 2026-03-31 | 2025-12 | 0.3 | -0.46 | -0.76 | -250.74% |
| 2025-09-30 | 2025-06 | -0.25 | -0.13 | 0.11 | 45.89% |
| 2025-04-02 | 2024-12 | -0.62 | -1.01 | -0.39 | -63.46% |
| 2024-11-12 | 2024-06 | -0.51 | -0.5 | 0.01 | 2.47% |
| 2024-04-24 | 2023-12 | -0.83 | -0.33 | 0.5 | 60.40% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-04 | Leerink Partners | Upgrade | Outperform | Outperform |
| 2026-05-01 | UBS | Upgrade | Neutral | Neutral |
| 2026-04-02 | Guggenheim | Upgrade | Buy | Buy |
| 2026-02-06 | Guggenheim | Upgrade | Buy | Buy |
| 2025-04-04 | Guggenheim | Upgrade | Buy | Buy |
| 2024-08-28 | Guggenheim | Upgrade | Buy |
Profile
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Johnson & Johnson | 5.62M | 214.94M | 11.11% |
| 2026-03-30 | Morgan Stanley | 36.27K | 1.39M | 0.07% |
| 2026-03-30 | Optiver Holding B.v. | 13.50K | 516.01K | 0.03% |
| 2026-03-30 | Marshall Wace LLP | 9.24K | 353.11K | 0.02% |
| 2026-03-30 | UBS Group AG | 5.56K | 212.39K | 0.01% |
| 2026-03-30 | BNP Paribas Financial Markets | 3.56K | 136.02K | 0.01% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 4.49K | 171.57K | 0.01% |
| 2026-04-29 | Steward Funds Inc-Steward Values Enhanced International Fund | 1.05K | 40.05K | 0.00% |
| 2026-05-30 | Trust for Professional Managers-ActivePassive International Equity ETF | 1.30K | 49.49K | 0.00% |